Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG (Nasdaq: CRSP) generates frequent news as a gene editing biopharmaceutical company advancing CRISPR/Cas9-based medicines and related platforms. News coverage commonly highlights progress with CASGEVY, described as the world’s first approved CRISPR-based therapy for eligible sickle cell disease and transfusion-dependent beta thalassemia patients, along with updates on the company’s expanding in vivo and cell therapy pipeline.
Investors and observers following CRSP news can expect regular announcements on clinical trial data, such as Phase 1 and Phase 2 results for programs like CTX310 targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and zugo-cel (zugocaptagene geleucel) in autoimmune diseases and B-cell malignancies. Company press releases also report on regulatory milestones and commercialization developments for CASGEVY across multiple regions, including approvals, reimbursement agreements, and pediatric development plans.
CRISPR Therapeutics’ news flow also includes pipeline and platform updates for in vivo liver editing programs (CTX310, CTX320, CTX321, CTX340, CTX450), SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, and regenerative medicine efforts in Type 1 diabetes. Collaboration announcements with partners such as Vertex Pharmaceuticals, Sirius Therapeutics, and Lilly, as well as participation in major scientific and investor conferences, are additional recurring themes.
On Stock Titan’s CRSP news page, readers can review these press releases and third-party articles in one place, track how clinical, regulatory, and partnership developments evolve over time, and use this information as context when assessing CRISPR Therapeutics’ stock and long-term gene editing strategy.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on gene-based medicines for serious diseases, announced its participation in upcoming investor conferences. Their senior management team will present at the Jefferies Healthcare Conference on June 5, 2024, at 10:00 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 9:20 a.m. ET. Live webcasts of these presentations will be accessible on the Investor section of the company's website and archived for 14 days post-event.
CRISPR Therapeutics (Nasdaq: CRSP) has announced key executive appointments. Dr. Naimish Patel will join as Chief Medical Officer effective May 28, 2024. Dr. Patel brings extensive experience from Sanofi, where he led the Global Development Therapeutic Area of Immunology and Inflammation. Additionally, Julianne Bruno has been promoted to Chief Operating Officer effective May 23, 2024. Ms. Bruno has been with CRISPR Therapeutics since 2019 and played a important role in the partnership with Vertex. These leadership changes aim to bolster CRISPR Therapeutics' capabilities in advancing its portfolio of gene-based medicines for serious diseases.
CRISPR Therapeutics will be presenting at the Bank of America Securities Health Care Conference on May 15, 2024. The company's senior management team will discuss their transformative gene-based medicines for serious diseases. The event will be live webcasted and available for replay on the company's website.
CRISPR Therapeutics reported strong financial results for the first quarter of 2024, with a focus on expanding its pipeline and advancing clinical trials. The company has over 25 authorized treatment centers globally for CASGEVY™ and has activated multiple clinical trials for next generation CAR T and in vivo gene editing products. CRISPR Therapeutics also expanded its pipeline with new preclinical programs targeting refractory hypertension and acute hepatic porphyria. The company reported a strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024.
CRISPR Therapeutics presented new preclinical data at the ASGCT meeting, highlighting in vivo gene editing using lipid nanoparticles for ocular and liver targets. The company introduced two new programs, CTX340 and CTX450, demonstrating promising results for refractory hypertension and acute hepatic porphyria. Clinical trials for these programs are set to begin in the second half of 2025. Additionally, the company showcased its ability to edit genes in the eye for potential glaucoma treatments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
